Schrodinger Inc
$ 11.98
-12.11%
11 Feb - close price
- Market Cap 1,004,050,000 USD
- Current Price $ 11.98
- High / Low $ 13.74 / 11.79
- Stock P/E N/A
- Book Value 4.36
- EPS -2.40
- Next Earning Report 2026-02-25
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.16 %
- ROE -0.46 %
- 52 Week High 28.47
- 52 Week Low 11.79
About
Schrodinger Inc. (SDGR) is a leading innovator in the field of computational drug design, harnessing its sophisticated physics-based software platform to revolutionize the discovery and optimization of novel therapeutic and material compounds. Headquartered in New York, the company leverages cutting-edge computational methodologies to enhance efficiency, reduce costs, and accelerate time-to-market for pharmaceuticals. Its strategic partnerships with biotech and pharmaceutical firms position Schrodinger as an indispensable ally in overcoming the intricate challenges of drug development, making it an attractive opportunity for institutional investors seeking exposure to transformative advancements in healthcare and materials science.
Analyst Target Price
$25.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-06 | 2025-04-29 | 2025-02-26 | 2024-11-12 | 2024-07-31 | 2024-05-01 | 2024-02-28 | 2023-11-01 | 2023-08-02 | 2023-05-04 | 2023-02-28 |
| Reported EPS | -0.45 | -0.59 | -0.64 | -0.24 | -0.5233 | -0.74 | -0.76 | -0.41 | -0.86 | 0.06 | 1.75 | -0.38 |
| Estimated EPS | -0.71 | -0.8 | -0.81 | -0.38 | -0.6 | -0.85 | -0.75 | -0.38 | -0.71 | -0.47 | 1.31 | -0.53 |
| Surprise | 0.26 | 0.21 | 0.17 | 0.14 | 0.0767 | 0.11 | -0.01 | -0.03 | -0.15 | 0.53 | 0.44 | 0.15 |
| Surprise Percentage | 36.6197% | 26.25% | 20.9877% | 36.8421% | 12.7833% | 12.9412% | -1.3333% | -7.8947% | -21.1268% | 112.766% | 33.5878% | 28.3019% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-25 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.13 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SDGR
2026-02-05 04:59:35
This article analyzes Schrodinger Inc. (NASDAQ: SDGR) volatility using AI models, indicating weak sentiment across all time horizons which supports a short bias. It provides three trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop loss points. The analysis highlights elevated downside risk and presents multi-timeframe signal data for support and resistance levels.
2026-02-04 10:28:41
Schrödinger Inc. (NASDAQ:SDGR) recently experienced a 26% stock price drop over thirty days, adding to a 46% decline over the past year. Despite this, its Price-to-Sales (P/S) ratio of 3.8x remains higher than the Healthcare Services industry average of 2.2x. The elevated P/S ratio is attributed to the company's strong revenue growth (33% last year, 51% over three years) and positive future revenue forecasts, with analysts expecting a 16% annual climb for the next three years, outpacing the industry's 13% forecast.
2026-02-04 00:29:10
Schrodinger Inc.'s stock (SDGR) has hit a new 52-week low of $13.43, marking a 43% decrease over the past year, despite the company's strong balance sheet and impressive revenue growth. Analysts have mixed ratings, but some believe the stock may be undervalued and are optimistic about its strategic shift towards software operations and AI-enhanced drug discovery collaborations. Investors are closely monitoring the situation as the stock reaches a critical juncture.
2026-02-03 17:31:48
Schrodinger Inc. (SDGR) stock has fallen to a new 52-week low of $13.43, marking a 43% decrease over the past year. Despite this, the company maintains a strong balance sheet and has shown impressive revenue growth, with InvestingPro suggesting the stock may be undervalued and in oversold territory. Schrodinger also recently announced a collaboration with Lilly TuneLab to enhance drug discovery and outlined strategic priorities for fiscal year 2026, receiving mixed analyst ratings.
2026-02-03 16:28:48
Schrodinger Inc. (SDGR) stock has fallen to a new 52-week low of $13.43, representing a 43% decrease over the past year. Despite this, the company maintains a strong financial position with more cash than debt and robust revenue growth, and analysts suggest the stock may be undervalued. Recent developments include a collaboration with Lilly TuneLab to enhance drug discovery and a strategic refocus on software operations and preclinical development, leading to mixed but generally optimistic analyst ratings.
2026-01-31 07:03:30
Wall Street Zen has upgraded Schrodinger (NASDAQ:SDGR) from a "sell" to a "hold" rating, contributing to an average "Hold" rating and a $24.33 target price across analysts. Despite beating revenue and EPS estimates last quarter, the company remains unprofitable with a negative net margin. Institutional investors have actively adjusted their stakes in Schrodinger, with a significant portion of the stock owned by hedge funds and other institutional investors.
